Tacrolimus Capsules USP 0.5 mg, 1 mg, 5 mg

Hazard statements (CLP)

H351, H360, H373

Code

Statements

H351

Suspected of causing cancer

SECTION 2: Hazards identification

GHS US classification Classification of the substance or mixture GHS-US classification Carc. 2 H351 Repr. 1B H360 STOT RE 2 H373 Full text of H statements : see section 16

2.2 Label elements

GHS-US labelling

Hazard pictograms

GHS08

Signal word

Danger

Hazard statements

H351 - Suspected of causing cancer H360 - May damage fertility or the unborn child H373 - May cause damage to organs (kidneys, thymus, spleen, pancreas, lymphoid system, bone marrow) through prolonged or repeated exposure

Precautionary statements

P201 - Obtain special instructions before use P202 - Do not handle until all safety precautions have been read and understood P260 - Do not breathe dust P280 - Wear protective gloves P308+P313 - If exposed or concerned: Get medical advice/attention P314 - Get medical advice/attention if you feel unwell P405 - Store locked up P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation

2.3 Other hazards

No additional information available

Ingredient(s) with unknown acute toxicity

17.86 percent of the mixture consists of ingredient(s) of unknown acute toxicity (Oral) 17.86 percent of the mixture consists of ingredient(s) of unknown acute toxicity (Dermal) 17.86 percent of the mixture consists of ingredient(s) of unknown acute toxicity (Inhalation (Dust/Mist))

2.1 Classification of the substance or mixture

GHS-US classification Carc. 2 H351 Repr. 1B H360 STOT RE 2 H373 Full text of H statements : see section 16